STOMACH

Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs

C J Hawkey¹, J Næsdal², I Wilson², G Långström², A J Swannell³, R A Peacock², N D Yeomans⁴

¹ Division of Gastroenterology, University Hospital, Queen’s Medical Centre, Nottingham, UK
² AstraZeneca R&D Mölndal, S-431 83 Mölndal, Sweden
³ Department of Rheumatology, City Hospital, Hucknall Road, Nottingham, UK
⁴ Department of Medicine, University of Melbourne, Western Hospital, Footscray, Victoria 3011, Australia

Correspondence to:
Correspondence to:
C J Hawkey, Division of Gastroenterology, University Hospital, Queen’s Medical Centre, Nottingham NG7 2UH, UK;
cj.hawkey{at}nottingham.ac.uk

Background and aims: A past history of peptic ulceration increases the risk of an ulcer developing during non-steroidal anti-inflammatory drug (NSAID) use. Whether this is due to Helicobacter pylori infection or to reactivation of the original lesion is unclear.

Methods: We used multivariate regression analyses of three large similar trials to identify factors that placed patients at high risk of ulcer development or relapse. We compared the efficacy of omeprazole 20 mg daily, misoprostol 200 µg twice daily, and ranitidine 150 mg twice daily in preventing ulcers and erosions at different sites and in patients who were H pylori positive and negative.

Results: Patients with endoscopic lesions (which healed) initially were significantly more likely than those without to develop further erosions or ulcers during treatment (rate ratio 2.12, 1.07–4.17). Risk mounted further with ulcers versus erosions, particularly those that had been slow to heal. There was a highly significant tendency for the relapse lesion to replicate the site and type of the original lesion (mean odds ratios ranging from 3 to 14). Treatment failure was significantly less likely with omeprazole than with placebo, misoprostol, or ranitidine. This advantage was especially evident in H pylori positive patients receiving acid suppression (5.7% v 16.6% for gastric ulcer with omeprazole).

Conclusions: Relapse of lesions in patients taking NSAIDs was highly site and type specific and not adversely affected by H pylori status. This strongly implies that local mucosal factors predispose to ulcer development in patients taking NSAIDs. Identification of the responsible mucosal changes would aid understanding and could promote better treatment.

Keywords: non-steroidal anti-inflammatory drugs; Helicobacter pylori; gastric ulcer; duodenal ulcer; gastric erosions

Abbreviations: NSAIDs, non-steroidal anti-inflammatory drugs; RR, rate ratio; OR, odds ratio; GU, gastric ulcer; DU, duodenal ulcer; DDD, defined daily dose

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Articles

Digest

Ian Forgacs
Gut 2002 51: 301. [Extract] [Full Text] [PDF]

Relative contribution of mucosal injury and Helicobacter pylori in the development of gastroduodenal lesions in patients taking non-steroidal anti-inflammatory drugs

C J Hawkey, J Næsdal, I Wilson, G Långström, A J Swannell, R A Peacock, and N D Yeomans
Gut 2002 51: 336-343. [Abstract] [Full Text] [PDF]

Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users

C J Hawkey, I Wilson, J Næsdal, G Långström, A J Swannell, and N D Yeomans
Gut 2002 51: 344-350. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Dickman, A., Ellershaw, J. (2004). For Discussion NSAIDs: gastroprotection or selective COX-2 inhibitor?. Palliat Med 18: 275-286 [Abstract]  
• Hawkey, C J, Langman, M J S (2003). Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut 52: 600-608 [Abstract] [Full Text]  
• Hawkey, C J, Wilson, I, Naesdal, J, Langstrom, G, Swannell, A J, Yeomans, N D (2002). Influence of sex and Helicobacter pylori on development and healing of gastroduodenal lesions in non-steroidal anti-inflammatory drug users. Gut 51: 344-350 [Abstract] [Full Text]